GBP10.69
0.42% yesterday
London, May 29, 05:40 pm CET
ISIN
GB0009223206
Symbol
SN
Sector

Smith & Nephew Stock price

GBP10.69
+0.73 7.33% 1M
+0.88 8.95% 6M
+0.93 9.57% YTD
+1.14 11.90% 1Y
-1.45 11.92% 3Y
-3.76 26.04% 5Y
+1.41 15.17% 10Y
London, Closing price Thu, May 29 2025
+0.05 0.42%
ISIN
GB0009223206
Symbol
SN
Sector

Key metrics

Market capitalization GBP9.31b
Enterprise Value GBP11.32b
P/E (TTM) P/E ratio 30.54
EV/FCF (TTM) EV/FCF 25.21
EV/Sales (TTM) EV/Sales 2.63
P/S ratio (TTM) P/S ratio 2.16
P/B ratio (TTM) P/B ratio 2.40
Dividend yield 2.67%
Last dividend (FY24) GBP0.29
Revenue growth (TTM) Revenue growth 4.70%
Revenue (TTM) Revenue GBP4.30b
EBIT (operating result TTM) EBIT GBP622.99m
Free Cash Flow (TTM) Free Cash Flow GBP448.91m
Cash position GBP458.54m
EPS (TTM) EPS GBP0.35
P/E forward 19.77
P/S forward 2.07
EV/Sales forward 2.51
Short interest 128.00%
Show more

Is Smith & Nephew a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Smith & Nephew Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Smith & Nephew forecast:

10x Buy
53%
9x Hold
47%

Analyst Opinions

19 Analysts have issued a Smith & Nephew forecast:

Buy
53%
Hold
47%

Financial data from Smith & Nephew

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4,304 4,304
5% 5%
100%
- Direct Costs 1,307 1,307
2% 2%
30%
2,997 2,997
6% 6%
70%
- Selling and Administrative Expenses 2,028 2,028
3% 3%
47%
- Research and Development Expense 214 214
15% 15%
5%
755 755
25% 25%
18%
- Depreciation and Amortization 132 132
14% 14%
3%
EBIT (Operating Income) EBIT 623 623
38% 38%
14%
Net Profit 305 305
57% 57%
7%

In millions GBP.

Don't miss a Thing! We will send you all news about Smith & Nephew directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Deepak Nath
Employees 17,349
Founded 1856
Website www.smith-nephew.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today